Secondary CMV disease may occur in CMV- seropositive (R+) SOT recipients, either as reactivation (of endogenous latent CMV in the recipient) or super- infection (with CMV transmitted by transplantation) ( 23). Allostimulation, allograft rejection, and intense pharmacologic immunosuppression, particularly with antithymocyte-immunoglobulin therapy, combine to provide an environment that permits CMV reactivation after SOT ( 25)
If you want to change selection, open document below and click on "Move attachment"
pdf
owner:
memeyrie - (no access) - CMV ASM.pdf, p3
Summary
| status | not read | | reprioritisations | |
|---|
| last reprioritisation on | | | suggested re-reading day | |
|---|
| started reading on | | | finished reading on | |
|---|
Details